Huntington's disease: present treatments and future therapeutic modalities

Area of Science:

• Neuroscience
• Genetics
• Pharmacology

Background:

• Huntington's disease (HD) is a severe neuropsychiatric disorder with limited therapeutic options.
• Despite gene discovery in 1993, effective treatments remain elusive, offering only slight symptomatic relief.
• Research has disproportionately focused on motor symptoms, neglecting significant behavioral issues like dementia and depression.

Purpose of the Study:

• To review available double-blind, placebo-controlled, and open-label trials for Huntington's disease therapies.
• To assess the clinical relevance of current treatment recommendations for HD.
• To identify potential therapeutic strategies for both motor and behavioral aspects of HD.

Main Methods:

• Systematic review of double-blind, placebo-controlled trials.
• Inclusion of relevant open-label studies and case reports.
• Analysis of 24 key studies to evaluate treatment efficacy.

Main Results:

• Overall evidence for effective Huntington's disease management is poor.
• No treatment recommendation with significant clinical relevance emerged from the analyzed studies.
• Specific drug classes (riluzole, olanzapine, amantadine, SSRIs, mirtazapine, atypical antipsychotics) are suggested for symptom management based on limited data.

Conclusions:

• Current therapeutic interventions for Huntington's disease lack robust evidence.
• A shift in research focus towards behavioral and cognitive symptoms is crucial.
• Multidisciplinary management including psychotherapy and therapies is recommended alongside pharmacological approaches.